CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 11 2025
0mins
Source: Globenewswire
CytomX Therapeutics Offering: CytomX Therapeutics announced a public offering of 76,923,076 shares of common stock at $1.30 per share, aiming to raise approximately $100 million for research and development, corporate purposes, and working capital.
Company Overview: CytomX is focused on developing conditionally activated biologic therapeutics for cancer treatment, with a pipeline that includes innovative therapies such as CX-2051 and CX-801, and collaborations with major oncology firms.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
